KIKELOMO DAWOTOLA: Open Payments
NPI 1093285504 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$844 in 32 payments from 6 companies in 2025. Trend: 2023 $495 · 2024 $958 · 2025 $844
Food & beverage: $746Education: $98
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 21 | $558 |
| Alkermes, Inc. | 4 | $120 |
| Luye Pharma (USA) Ltd. | 4 | $100 |
| Neurocrine BioSciences, Inc. | 1 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| ABBVIE INC. | 1 | $16 |
Products named: AUSTEDO XR, ARISTADA, ERZOFRI EXTENDED-RELEASE, INGREZZA, CAPLYTA, VRAYLAR.
Industry payments across TX — which companies pay providers there.
